Can-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancer - CANF News | RalliesCan-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancer
C
CANF• Preclinical evidence supports planned Phase IIb trial
- Can-Fite outlined new preclinical evidence that namodenoson could strengthen chemotherapy’s anti-cancer effect in pancreatic cancer.
- The work supports a planned Phase IIb trial using namodenoson with gemcitabine and nab-paclitaxel in advanced pancreatic adenocarcinoma.
- Findings point to a clearer cell-death response, suggesting the drug may make tumors more vulnerable to standard chemotherapy.
- Phase IIa clinical results for namodenoson in advanced pancreatic adenocarcinoma will be presented at ESMO Congress 2026.
TLT
•
